33 results about "Cyclophilin A" patented technology

The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one binding site of Cyclophilin A on the HIV capsid protein. (SEQ ID NOS: 2, 4, and 6) The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NOS: 2, 4, and 6), messenger RNA, or DNA / RNA. DNA / RNA compositions (SEQ ID NOS 1, 3, 5, 7, 9, and 11) may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.

A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.

The present invention is directed to a method for the lowering of levels of LDL cholesterol in an individual comprising administering to the individual an agent which modulates the activity of the protein annexin 2, cyclophilin A, cyclophilin 40, or HSP 56 or the complex of annexin 2 and caveolin I, in the intestinal cells of the individual.

The object of the present invention is to provide an early mastitis detection method that can detect mastitis easily and quickly when compared to the prior methods and also a biomarker to be used with the method.The object can be solved by a method of examining a mammary gland disease by using the level of cyclophilin A in a mammary gland or in milk as indicator. More specifically, the object can be a method of examining a mammary gland disease comprising steps (1) and (2) listed below;(1) a step of detecting cyclophilin A in the milk collected from an udder or an udder quarter of a subject and thereby determining the cyclophilin A level in the milk; and(2) a step of determining the onset of a mammary gland disease or the possibility of onset of a mammary gland disease in the udder or the udder quarter of the subject on the basis of the cyclophilin A level in the milk.

The present invention relates to enhancing, modulating or stimulating the innate immune response to HIV-1 and other viral pathogens and to the modulation and application of immune modulators and peptides for HIV-1 or other pathogen vaccines. The invention provides methods and means to activate an innate response to HIV-1 utilizing or via the HIV capsid protein or peptide, including modulating the binding of cyclophilin A to HIV capsid protein and modulating the ability of HIV to activate the major innate transcription factor IRF3 and interferon. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating innate immune response, particularly to HIV-1.

The invention belongs to the field of the tumor molecule biology, in particular to a diagnosis reagent, a reagent knit and prevention and cure drugs of endometrial carcinoma, which provides a new diagnosis reagent and medicine for the early diagnosis and the prevention of endometrial carcinoma, and also provides a new method for filtering the medicine used for preventing endometrial carcinoma. The diagnosis reagent for endometrial carcinoma of the invention contains a reagent which can test the expressing level of a human cyclophilin A protein or the content of the mRNA of genes of the human cyclophilin A protein. The medicine which can prevent endometrial carcinoma of the invention includes: the expressing carrier of a shPNA molecule which can express the human cyclophilin A, etc. can change the expressing level of the human cyclophilin A protein or the mRNA content of the genes of the human cyclophilin A protein. The diagnosis reagent of the invention can be used for the early diagnosis of endometrial carcinoma, which has a wide application prospect.

The present invention constructs red ray (Dasytis akajei) tail thorn cDNA library and DNA sequencing, and according to the obtained cyclophilin (CyP) EST 3' end and carrier nucleotide sequence, designs primers, uses the method of PCR, from The full-length cyclophilin A gene was screened and cloned from the red ray sting cDNA library. The length of the new gene is 656bp, and it encodes a mature peptide of 167 amino acids. The expressed protein has an isoelectric point of 8.34 and a molecular weight of about 18,021 Daltons. The red stingray thorn cyclophilin A gene was cloned at the 3' end of the trxA gene of the thioredoxin gene fusion expression vector pTRX, and a fusion gene in line with the reading frame was constructed. The fusion protein was soluble in E. coli as an intracellular Form exists, the expression amount can reach 60mg / L. Through Ni-Chelating affinity chromatography, protease 3C cleavage and gel filtration, the mature recombinant red ray cyclophilin A protein with a purity of more than 95% was obtained, with a yield of 10 mg / L. The protein has peptidylproline cis-trans isomerase activity.

An object of the present invention is to provide a novel examination method for a cardiovascular disease. As means for achieving the object, provided is an examination method for a cardiovascular disease, the method including the steps of: measuring a concentration of cyclophilin A protein in a human blood sample; and determining a probability of development of a cardiovascular disease based on the measured concentration of cyclophilin A protein.

The invention discloses a Rotavirus-resistant drug acting target which is a composite three-dimensional structure model of interaction of rotavirus VP6 protein and human Cyclophilin A, wherein the functional zone of the VP6 protein is amino acid from 52th to 100th site and amino acid from 349th to 392th site, and the active site comprises Asn 53, Ala 348, Val 349, Ile 355 and Pro 363; and the functional zone of the Cyclophilin A is amino acid from 54th to150th site, and the active site comprises Arg 55, Gln 63, Lys 125 and Arg 148. The invention also discloses a building method and an application method of the target; and the target and the application method thereof can simply and fast screen or design a compound capable of blocking the interaction of the rotavirus VP6 protein and the human Cyclophilin A; the invention researches and develops a specificity Rotavirus-resistant drug which is efficient and harmfulless; and the building method of the target is favor of the building of acting targets of other drugs.

The invention discloses a kit for specific detection of endometrial cancer. An aptamer provided in the invention has good affinity to human Cyclophilin A protein. Cyclophilin A protein in blood can be captured through the aptamer, and endometrial cancer can be detected through content variation of Cyclophilin A protein. The aptamer is prepared into a corresponding kit to be used for screening of endometrial cancer. The kit has the advantages of high sensitivity and low cost.

The invention discloses a kit for specific detection of endometrial cancer. An aptamer provided in the invention has good affinity to human Cyclophilin A protein. Cyclophilin A protein in blood can be captured through the aptamer, and endometrial cancer can be detected through content variation of Cyclophilin A protein. The aptamer is prepared into a corresponding kit to be used for screening of endometrial cancer. The kit has the advantages of high sensitivity and low cost.

The inventio discloses a hybridoma cell, a monoclonal antibody for anti-human cyclophilin A and an application thereof. The invention adopts a traditional cell hybridoma preparation technique for acquiring a hybridoma cell strain for stably secreting the monoclonal antibody of the anti-human cyclophilin A (cyclophilin A, CypA). The preservation number of the hybridoma cell is CCTCC NO: C201126; the secreted antibody can specifically identify CypA protein molecules expressed in various tissues of a human body; and a new effective tool is provided for diagnosing and treating cancers and inflammations.

The invention discloses a kit for specific detection of endometrial cancer. An aptamer provided in the invention has good affinity to human Cyclophilin A protein. Cyclophilin A protein in blood can be captured through the aptamer, and endometrial cancer can be detected through content variation of Cyclophilin A protein. The aptamer is prepared into a corresponding kit to be used for screening of endometrial cancer. The kit has the advantages of high sensitivity and low cost.

The invention relates to a recombination cyclophilin A antibody, a preparation method thereof, an enzyme-linked immuno sorbent assay (ELISA) kit and cell strains. The problems that process conditions are complex, the specificity is poor, and protein immunological activity loss is large in the process of preparing the existing recombination cyclophilin A antibody are solved. Induced bacteria whichare purified or not purified immunize experiment animals, and a specific polyclonal antibody or a specific monoclonal antibody of the recombination cyclophilin A can be obtained through screening andpurification. The recombination cyclophilin A antibody is prepared through the preparation method. A solid phase carrier and a detection antibody in the ELISA kit contain the recombination cyclophilin A antibodies. The preparation method of the recombination cyclophilin A antibody has the advantages that the process conditions are simple, the specificity is good, the purification is simple, the protein immunological activity loss is less, and the operation is convenient.

The invention discloses a kit for specific detection of endometrial carcinoma. An aptamer has high affinity to human Cyclophilin A protein. By utilizing the aptamer, the Cyclophilin A protein in blood can be captured, and the endometrial carcinoma is detected through changes in content of the Cyclophilin A protein; after the aptamer is prepared to be the corresponding kit which is about to be used for screening the endometrial carcinoma. The kit has the advantages high sensitivity and low cost.

The invention discloses a kit for specific detection on endometrial cancer. The aptamer disclosed by the invention has relatively good affinity with human Cyclophilin A protein. By adoption of the aptamer disclosed by the invention, Cyclophilin A protein in blood can be captured, endometrial cancer can be detected according to variation of the content of the Cyclophilin A protein, and a corresponding kit can be prepared to screen endometrial cancer. The kit disclosed by the invention has the advantages of high sensitivity and low cost.